Search research articles
Contact Us
Filters
Showing results (181-190 of 268) with videos related to
Page
of 27
Sort By:
Pituitary
|
January 13, 2022
Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience
Roberto Salvatori, Pietro Maffei, Susan M Webb, et al.
Nature Reviews. Endocrinology
|
June 6, 2024
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management
Daniela Esposito, Cesar Luiz Boguszewski, Annamaria Colao, et al.
Endocrine
|
May 23, 2016
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study
James W Findling, Maria Fleseriu, John Newell-Price, et al.
Pituitary
|
December 1, 2025
Patient perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society international patient survey
Hidenori Fukuoka, Andrea Glezer, Niki Karavitaki, et al.
Pituitary
|
November 4, 2023
Consensus on criteria for acromegaly diagnosis and remission
Andrea Giustina, Nienke Biermasz, Felipe F Casanueva, et al.
Pituitary
|
January 1, 2022
Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
Maria Fleseriu, Ariel Barkan, Maria Del Pilar Schneider, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 5, 2020
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
Odelia Cooper, Vivien S Bonert, Jeremy Rudnick, et al.
Pituitary
|
December 5, 2023
Correction: consensus on criteria for acromegaly diagnosis and remission
Andrea Giustina, Nienke Biermasz, Felipe F Casanueva, et al.
Journal of Clinical Medicine
|
March 25, 2022
Clinical Study and Systematic Review of Pituitary Microadenomas vs. Macroadenomas in Cushing's Disease: Does Size Matter?
Amit Akirov, Ilan Shimon, Maria Fleseriu, et al.
Pituitary
|
October 11, 2022
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2)
Maria Fleseriu, Beverly M K Biller, Jérôme Bertherat, et al.
Page
of 27
Search research articles
Search
Showing results (181-190 of 268) with videos related to
Sort By:
Page
of 27
Pituitary
|
January 13, 2022
Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience
Roberto Salvatori, Pietro Maffei, Susan M Webb, et al.
Nature Reviews. Endocrinology
|
June 6, 2024
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management
Daniela Esposito, Cesar Luiz Boguszewski, Annamaria Colao, et al.
Endocrine
|
May 23, 2016
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study
James W Findling, Maria Fleseriu, John Newell-Price, et al.
Pituitary
|
December 1, 2025
Patient perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society international patient survey
Hidenori Fukuoka, Andrea Glezer, Niki Karavitaki, et al.
Pituitary
|
November 4, 2023
Consensus on criteria for acromegaly diagnosis and remission
Andrea Giustina, Nienke Biermasz, Felipe F Casanueva, et al.
Pituitary
|
January 1, 2022
Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
Maria Fleseriu, Ariel Barkan, Maria Del Pilar Schneider, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 5, 2020
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
Odelia Cooper, Vivien S Bonert, Jeremy Rudnick, et al.
Pituitary
|
December 5, 2023
Correction: consensus on criteria for acromegaly diagnosis and remission
Andrea Giustina, Nienke Biermasz, Felipe F Casanueva, et al.
Journal of Clinical Medicine
|
March 25, 2022
Clinical Study and Systematic Review of Pituitary Microadenomas vs. Macroadenomas in Cushing's Disease: Does Size Matter?
Amit Akirov, Ilan Shimon, Maria Fleseriu, et al.
Pituitary
|
October 11, 2022
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2)
Maria Fleseriu, Beverly M K Biller, Jérôme Bertherat, et al.
Page
of 27